Navigation Links
Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
Date:1/20/2012

SEATTLE, Jan. 20, 2012  /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, following discussions with the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP"), the CHMP may issue an opinion on CTI's Marketing Authorization Application ("MAA") for Pixuvri in mid-February. In the interim, CTI will continue to work with the CHMP on the Summary of Product Characteristics and other labeling items for Pixuvri. CTI is seeking an authorization to market Pixuvri in the E.U. for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin's B cell lymphomas ("NHL"). If approved by the EMA, Pixuvri would address an unmet medical need, as there are no approved therapies for these patients.

In the U.S., the Food and Drug Administration ("FDA") has set a Prescription Drug User Fee Act ("PDUFA") goal date of April 24, 2012 for a decision on the New Drug Application for Pixuvri in the same indication.

About Pixuvri (pixantrone)

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory B cell NHL without unacceptable rates of cardio toxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,

http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Pixuvri in particular, including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that CTI may not receive a positive opinion regarding the MAA from the CHMP in mid-February 2012 or at all, that the CHMP may reschedule timing of the issuance of its opinion on the MAA, that the CHMP may request additional information from CTI regarding Pixuvri, that CTI may not obtain a license to market Pixuvri in the E.U., that the EMA and/or the European Commission may not formally adopt the CHMP's opinion regarding Pixuvri, that the FDA may not complete the review of the New Drug Application for Pixuvri by the PDUFA goal date of April 24, 2012, that CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling Pixuvri, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
2. European mountain vegetation shows effects of warmer climate
3. DTU is participating in a European network on measurement of greenhouse gases
4. Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux
5. UK invests £75 million in European research infrastructure to support knowledge-based economy
6. EMBO awards Installation Grants to 7 European scientists
7. How does a plant survive with few mates or pollinators? A European herb has figured out its own way
8. New European project launched to address shortcomings in climate data
9. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
10. Genomatix to partner in $41 million European epigenomics consortium
11. Pesticides pollute European waterbodies more than previously thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: AWRE), ... that Richard P. Moberg has resigned, effective ... and Chief Financial Officer and Treasurer of Aware citing ... serve as a member of the Board of Directors ... Aware,s co-Chief Executive Officer and co-President, General Counsel has ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
Breaking Biology Technology: